Mostrando 1 - 5 Resultados de 5 Para Buscar 'Arrese, Marco', tiempo de consulta: 0.01s Limitar resultados
1
artículo
Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports
Publicado por
Hernández, Nelia, Bessone, Fernando, Sánchez, Adriana, Di Pace, María, Brahm, Javier, Zapata, Rodrigo, Chirino, Ruby A., Dávalos, Milagros, Méndez-Sánchez, Nahum, Arrese, Marco, Schinoni, María, Lucena, M. Isabel, Andrade, Raúl
Publicado 2014 Enlace
Se realizó una búsqueda bibliográfica utilizando la versión en línea de MEDLINE, EMBASE, Scopus, Google Scholar y bases de datos específicas de América Latina para identificar cualquier informe de caso o serie de casos de lesión hepática inducida por drogas publicados desde 1996 hasta 2012.
Agregar a favoritos
Guardado en:
3
artículo
Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population
Publicado por
Zambrano-Huailla, Rommel, Guedes, Laura, Stefano, Jose Tadeu, de Souza, Arthur A. Arrais, Marciano, Sebastián, Yvamoto, Erika, Michalczuk, Matheus Truccolo, Vanni, Denise Siqueira, Rodriguez, Hernan, Carrilho, Flair Jose, Alvares-da-Silva, Mario Reis, Gadano, Adrian, Arrese, Marco, Miranda, Adelina Lozano, Oliveira, Claudia P.
Publicado 2020 Enlace
Introduction and aims Several non-invasive scoring systems have been developed and validated worldwide to predict the risk of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). However, information about the performance of these systems in Latin American populations is scarce. Our aim was to evaluate the performance of the Hepamet Fibrosis Score, Fibrosis-4 (FIB-4) and the NAFLD Fibrosis Score (NFS) in a mixed Latin American group of NAFLD patients. Methods Clinical, laboratory and liver biopsy data collected from 379 biopsy-proven NAFLD patients from Latin American tertiary health centers were reviewed. Histological fibrosis stages were classified using the Kleiner score. Accuracy was determined, and new fibrosis score thresholds were calculated to better compare the performances of non-invasive tests and to explore their usefulness in excluding fibrosis. Results The distributi...
Agregar a favoritos
Guardado en:
4
artículo
Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease
Publicado por
Arab, Juan Pablo, Dirchwolf, Melisa, Álvares-da-Silva, Mário Reis, Barrera, Francisco, Benítez, Carlos, Castellanos-Fernandez, Marlene, Castro-Narro, Graciela, Chavez-Tapia, Norberto, Chiodi, Daniela, Cotrim, Helma, Cusi, Kenneth, de Oliveira, Claudia Pinto Marques Souza, Díaz, Javier, Fassio, Eduardo, Gerona, Solange, Girala, Marco, Hernandez, Nelia, Marciano, Sebastián, Masson, Walter, Méndez-Sánchez, Nahum, Leite, Nathalie, Lozano, Adelina, Padilla, Martín, Panduro, Arturo, Paraná, Raymundo, Parise, Edison, Perez, Marlene, Poniachik, Jaime, Restrepo, Juan Carlos, Ruf, Andrés, Silva, Marcelo, Tagle, Martín, Tapias, Monica, Torres, Kenia, Vilar-Gomez, Eduardo, Costa Gil, José Eduardo, Gadano, Adrian, Arrese, Marco
Publicado 2020 Enlace
Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chronic liver disease, affecting 20–30% of the general population. Furthermore, its prevalence is predicted to increase exponentially in the next decades, concomitantly with the global epidemic of obesity, type 2 diabetes mellitus (T2DM), and sedentary lifestyle. NAFLD is a clinical syndrome that encompasses a wide spectrum of associated diseases and hepatic complications such as hepatocellular carcinoma (HCC). Moreover, this disease is believed to become the main indication for liver transplantation in the near future. Since NAFLD management represents a growing challenge for primary care physicians, the Asociación Latinoamericana para el Estudio del Hígado (ALEH) has decided to organize this Practice Guidance for the Diagnosis and Treatment of Non-Alcoholic F...
Agregar a favoritos
Guardado en:
5
artículo
Genetic Ancestry, Race, and Severity of Acutely Decompensated Cirrhosis in Latin America
Publicado por
Farias, Alberto Queiroz, Vilalta, Anna Curto, Zitelli, Patrícia Momoyo, Pereira, Gustavo, Goncalves, Luciana L., Torre, Aldo, Diaz, Juan Manuel, Gadano, Adrian C., Mattos, Angelo Z., Mendes, Liliana S.C., Alvares-da-Silva, Mario R., Bittencourt, Paulo L., Benitez, Carlos, Couto, Claudia Alves, Mendizabal, Manuel, Toledo, Claudio L., Mazo, Daniel F., Barradas, Mauricio Castillo, Uson Raposo, Eva M., Padilla-Machaca, P. Martín, Lozano Miranda, Adelina Zarela, Malé-Velázquez, René, Lyra, André Castro, Dávalos-Moscol, Milagros B., Pérez Hernandez, Jose L, Ximenes, Rafael O., Silva, Giovanni Faria, Beltrán-Galvis, Oscar A., González Huezo, María S., Bessone, Fernando, Rocha, Tarciso D.S., Fassio, Eduardo, Terra, Carlos, Marín, Juan I., Casas, Patricia Sierra, Peña-Ramirez, Carlos de la, Parera, Ferran Aguilar, Fernandes, Flavia, da Penha Zago-Gomes, Maria, Méndez-Guerrero, Osvely, Marciano, Sebastián, Mattos, Angelo A., Oliveira, Joao C., Guerreiro, Gabriel T.S., Codes, Liana, Arrese, Marco, Nardelli, Mateus J., Silva, Marcelo O., Palma-Fernandez, Renato, Alcantara, Camila, Garrido, Cristina Sánchez, Trebicka, Jonel, Gustot, Thierry, Fernández, Javier, Clària, Joan, Jalan, Rajiv, Angeli, Paolo, Arroyo, Vicente, Moreau, Richard, Carrilho, Flair J.
Publicado 2023 Enlace
BACKGROUND & AIMS: Genetic ancestry or racial differences in health outcomes exist in diseases associated with systemic inflammation (e.g., Covid-19). This study aimed to investigate the association of genetic ancestry and race with acute-onchronic liver failure (ACLF), which is characterized by acute systemic inflammation, multi-organ failure and high risk of short-term death. METHODS: This prospective cohort study analyzed a comprehensive set of data including genetic ancestry and race, among several others, in 1274 patients with acutely decompensated cirrhosis (ADC) who were nonelectively admitted to 44 hospitals from 7 Latin American countries. RESULTS: 395 (31.0%) had ACLF of any grade at enrollment. Patients with ACLF had higher median percentage of Native American genetic ancestry and lower median percentage of European ancestry than patients without ACLF (22.6% vs 12.9% and 53.4%...
Agregar a favoritos
Guardado en: